Glycogen synthase kinase−3β inhibitors suppress leukemia cell growth
Authors:
- Patricia PalladinettiPPPatricia Palladinetti
- Guy KlamerGKGuy Klamer
- Kap-Hyoun KoKKKap-Hyoun Ko
- Robert LindemanRLRobert Lindeman
- Tracey A. O'BRienTOTracey A. O'BRien
- Alla DolnikovADAlla Dolnikov
- 1 October 2010
- journal article
- Published by Elsevier in Experimental Hematology
- Vol. 38 (10) , 908-921.e1
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Glycogen synthase kinase 3: more than a namesakeBritish Journal of Pharmacology, 2009
- Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generationProceedings of the National Academy of Sciences, 2009
- Knockin of mutant PIK3CA activates multiple oncogenic pathwaysProceedings of the National Academy of Sciences, 2009
- Potential Therapeutic Effect of Glycogen Synthase Kinase 3β Inhibition against Human GlioblastomaClinical Cancer Research, 2009
- Systematic and integrative analysis of large gene lists using DAVID bioinformatics resourcesNature Protocols, 2008
- Elevated level of SUMOylated IRF-1 in tumor cells interferes with IRF-1-mediated apoptosisProceedings of the National Academy of Sciences, 2007
- Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor κB target genes and induction of apoptosis in chronic lymphocytic leukemia B cellsBlood, 2007
- The paradox of pro-inflammatory cytokines in cancerCancer and Metastasis Reviews, 2006
- Therapeutic-antagonists of oestrogens can be produced for cancer and other therapies using cytochromes P450 (CYP)Medical Hypotheses, 2005
- Maintenance of pluripotency in human and mouse embryonic stem cells through activation of Wnt signaling by a pharmacological GSK-3-specific inhibitorNature Medicine, 2003